Expulsion of micronuclei containing amplified genes contributes to a decrease in double minute chromosomes from malignant tumor cells

Wei Ji¹, Zehua Bian¹, Yang Yu¹, Chao Yuan¹, Yang Liu¹, Lisa Yu¹, Chunxiang Li¹, Jing Zhu¹, Xueyuan Jia¹, Rongwei Guan¹, Chunyu Zhang¹, Xiangning Meng¹, Yan Jin¹,², Jing Bai¹, Jingcui Yu¹, Ki-Young Lee⁴, Wenjing Sun¹ and Songbin Fu¹,²

¹ Laboratory of Medical Genetics, Harbin Medical University, Harbin, People’s Republic of China
² Key Laboratory of Medical Genetics (Harbin Medical University), Heilongjiang Higher Education Institutions, Harbin, People’s Republic of China
³ Scientific Research Center, The Second Affiliated Hospital, Harbin Medical University, Harbin, People’s Republic of China
⁴ Department of Cell Biology & Anatomy, Faculty of Medicine, University of Calgary, Calgary, AB, Canada

Double minute chromosomes (DMs) are a hallmark of gene amplification. The relationship between the formation of DMs and the amplification of DM-carried genes remains to be clarified. The human colorectal cancer cell line NCI-H716 and human malignant primitive neuroectodermal tumor cell line SK-PN-DW are known to contain many DMs. To examine the amplification of DM-carried genes in tumor cells, we performed Affymetrix SNP Array 6.0 analyses and verified the regions of amplification in NCI-H716 and SK-PN-DW tumor cells. We identified the amplification regions and the DM-carried genes that were amplified and overexpressed in tumor cells. Using RNA interference, we downregulated seven DM-carried genes, (NDUFB9, MTSS1, NSMCE2, TRIB1, FAM84B, MYC and FGFR2) individually and then investigated the formation of DMs, the amplification of the DM-carried genes, DNA damage and the physiological function of these genes. We found that suppressing the expression of DM-carried genes led to a decrease in the number of DMs and reduced the amplification of the DM-carried genes through the micronuclei expulsion of DMs from the tumor cells. We further detected an increase in the number of γH2AX foci in the knockdown cells, which provides a strong link between DNA damage and the loss of DMs. In addition, the loss of DMs and the reduced amplification and expression of the DM-carried genes resulted in a decrease in cell proliferation and invasion ability.

The amplification of oncogenes plays an important role in the malignant transformation of human cells and is associated with tumor development and drug resistance.¹,² The mechanism of amplification leading to the overexpression of oncogenes varies between different types of cancers.³,⁴ Double minute chromosomes (DMs) are DNA segments containing amplified oncogenes in tumor cells. DMs are small, paired, acentric and autonomously replicating extrachromosomal structures composed of circular DNA a few Mb in size.¹,⁵–⁹ DMs carrying amplified oncogenes are mostly present in solid tumors and neoplastic hematologic disorders.¹⁰ The frequency of DMs carrying oncogenes appears higher than the frequency of homogeneously staining regions (HSRs) in tumors.¹¹

Previous reports showed that the elimination of DMs from tumor cells was greatly accelerated by treating cells with a low concentration of hydroxyurea (HU); this also led to the reduced amplification of the oncogene C-MYC and the reversion of the malignant phenotype of colorectal carcinoma COLO320DM cells and promyelocytic leukemia HL-60 cells.¹²–¹⁴ Similar to this finding, the elimination of amplified multidrug resistance

Key words: gene amplification, double minute chromosomes, tumor, micronuclei

Additional Supporting Information may be found in the online version of this article.

This is an open access article under the terms of the Creative Commons Attribution-Non-Commercial-NoDerivs Licence, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

Grant sponsor: International Science & Technology Cooperation Program of China; Grant number: 2013DFA31610; Grant sponsor: Program for Changjiang Scholars and Innovative Research Team in University; Grant number: IRT1230; Grant sponsor: National Natural Science Foundation of China; Grant numbers: 31000626, 31271347; Grant sponsor: New Century Support Program for the Excellent Scholar, Ministry of Education of China; Grant number: NCET-10-0149, NCET-11-0954

DOI: 10.1002/ijc.28467

History: Received 12 July 2013; Accepted 22 Aug 2013; Online 30 Aug 2013

Correspondence to: Dr. Songbin Fu, 157 Baojian Road, Nangang District, Harbin 150081, People’s Republic of China, Tel.: 86-451-86674798, Fax: +86-451-86674798, E-mail: fusb@ems.hrbmu.edu.cn, fusongbin@yahoo.com; or Dr. Wenjing Sun, 157 Baojian Road, Nangang District, Harbin 150081, People’s Republic of China, Tel.: 86-451-86674798, Fax: +86-451-86674798, E-mail: sunwj@ems.hrbmu.edu.cn

Int. J. Cancer: 134, 1279–1288 (2014) © 2013 The Authors. Published by Wiley Periodicals, Inc. on behalf of UICC.
What’s new?
Double-minute chromosomes (DMs) are a hallmark of gene amplification and a major cytogenetic characteristic of malignant tumor cells. The function of DMs and DM-carried genes, however, remains to be clarified. Here, the authors identified amplification regions containing DM-carried genes that were themselves amplified and overexpressed in human malignant tumor cells. Knocking down the DM-carried amplified genes individually, they found that suppression of such oncogenes reduced the number of DMs, the amplification of these DM-carried genes, and cellular function. DNA damage and expulsion of micronuclei containing these DM-carried amplified genes may contribute to the decrease of DMs in tumor cells.

Antibodies and reagents
Antibodies against c-MYC and NDUFB9 were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The anti-TRIB1 antibody and the anti-NSMCE2 antibody were purchased from Abnova (Taipei, Taiwan). The anti-MTSS1 antibody was obtained from Abcam (Cambridge, MA). The anti-phospho-H2AX (Ser139) antibody was obtained from Millipore (Billerica, MA). The anti-mouse and anti-rabbit secondary antibodies, conjugated to fluorophores, were purchased from Rockland Immunochemicals (Gilbertsville, PA). The CF488 goat anti-mouse IgG (H+L) secondary antibodies were obtained from Biotium (Hayward, CA). Polyethyleneimine transfection reagent was obtained from Polysciences (Warrington, PA). The bacterial artificial chromosome (BAC) clones RP11–691H24, PR11–300114, RP11–150N13, PR11–89K10, PR11–440N18, and PR11–62L18 were obtained from BACPAC Resources Center (Children’s Hospital Oakland, Oakland, CA).

Affymetrix SNP Array 6.0 analysis
DNA was isolated from tumor cells and normal human peripheral blood using the QIAamp DNA Mini Kit (QIAGEN, Valencia, CA) and then applied to the Affymetrix GeneChip Human Mapping SNP6.0 array (Shanghai Biotechnology, Shanghai, China) to analyze the DNA copy number changes in the tumor cells.

Quantitative reverse transcriptase-polymerase chain reaction and quantitative polymerase chain reaction
Total RNA was isolated using TRIzol reagent (Invitrogen), according to the manufacturer’s protocol, and reverse transcribed into cDNA using the Transcriptor First Strand cDNA Synthesis Kit (Roche, Alameda, CA). DNA was routinely isolated from tumor cells and normal human peripheral blood. Polymerase chain reaction (PCR) analysis was performed on the cDNA and DNA using specific primers (Supporting Information Tables 1 and 2) under the following conditions: 94°C for 5 min; 45 cycles of 95°C for 5 sec, 60°C for 30 sec and 72°C for 30 sec; and 72°C for 7 min. The relative mRNA transcription and DNA amplification levels of each gene were normalized against ACTB mRNA and DNA levels, respectively.

Immunoblotting analysis
Cells were lysed for the immunoblotting analysis as described previously.23 The lysates were separated using 12%
Figure 1. Ten genes are amplified via DMs and overexpressed in NCI-H716 cells. (a) Four amplified regions (>3-fold) were determined by Affymetrix SNP Array 6.0 analysis in NCI-H716 cells. (b) Ten genes (NDUF9, MTSS1, ZNF572, SQLE, KIAA0196, NSMCE2, TRIB1, FAM84B, MYC and FGFR2) located on 8q24.13, 8q24.21 or 10q26.13 were at least 2-fold overexpressed compared to normal colon tissue using qRT-PCR analysis. (c) Ten genes (NDUF9, MTSS1, ZNF572, SQLE, KIAA0196, NSMCE2, TRIB1, FAM84B, MYC and FGFR2) were amplified by at least 2-fold compared to the normal human peripheral blood DNA using qPCR analysis. (d) The amplified regions were located on DMs in NCI-H716 cells. Representative images of FISH analyses are shown. The signals indicated the six BAC clones (RP11–691H24, PR11–300I14, RP11–150N13, RP11–89K10, RP11–440N18 and RP11–62L18) that specifically cover the ten amplified genes (NDUF9, MTSS1, ZNF572, SQLE, KIAA0196, NSMCE2, TRIB1, FAM84B, MYC and FGFR2). These probes mainly hybridized to the DMs in NCI-H716 cells. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
SDS-PAGE and then transferred onto polyvinylidene difluoride membranes, followed by incubation with the primary antibodies then the fluorescent-conjugated secondary antibodies. The fluorescent signals were visualized using the Odyssey imaging system (Li-COR, Lincoln, NE).

**Immunofluorescence analysis**

Cells were seeded onto coverslips in six-well plates for 24 hr for the immunofluorescence analysis, as described previously, and fixed with 4% paraformaldehyde. The coverslips were incubated with the anti-phospho-H2AX antibody, followed by the CF488 goat-anti-mouse IgG secondary antibodies. DNA was visualized by counterstaining the cells with 4,6-diamidino-2-phenylindole (DAPI). Images were obtained using a Leica DM5000B microscope (Leica Microsystems, Solms, Germany). To analyze the extent of the DNA damage, the cells were grouped into four categories according to their γH2AX signals, including no signal, 0–30% signals, 30–60% signals and 60–100% signals using ImageJ (National Institutes of Health, Bethesda, MD) software. The Mann–Whitney U-test was performed using the Statistical Package for the Social Sciences (SPSS v19.0, International Business Machines Corporation, New York, NY) program to assess the significant difference between the different groups.

**Preparation of metaphase spreads**

The cells were harvested for metaphase spread preparation according to a previous study and were then stained with Giemsa. Approximately 100 karyotypes of each group were observed under the microscope, and the numbers of DMs were counted. A t-test was used to analyze the statistical difference in the number of DMs for each group, and the statistical significance was accepted when \( p < 0.05 \).

**Fluorescence in situ hybridization analysis**

The BAC clones were used as DNA probes and were labeled with Spectrum Cy3-dUTP or Green-dUTP. The probes were then hybridized to interphase and metaphase spreads of tumor cells as described previously. Chromosomes were counterstained with DAPI. High-quality interphase and metaphase images were captured using a Leica DM5000 B fluorescence microscope and analyzed using the MetaMorph Imaging System (Universal Imaging, West Chester, PA).

**Cell proliferation, cell cycle distribution and cell invasion assays**

Cells were seeded in 96-well plates at \( 3 \times 10^3 \) cells per well. CellTiter 96®AQUEOUS One Solution Cell Proliferation Assay (Promega, WI) was used to measure the cell viability during a 4- to 6-day time course according to the manufacturer’s protocol. Three independent experiments were performed.

For the cell cycle distribution assay, the BD Cycletect™ Plus-DNA Reagent Kit (BD Biosciences, Bedford, MA) was used according to the manufacturer’s protocol and as described previously. The cells were harvested by...
trypsinization, washed in ice-cold PBS and then fixed using ice-cold 75% ethanol at 4°C for 24 hr. The cellular DNA was stained according to the manufacturer’s protocol. Cell cycle distribution was analyzed using flow cytometry analysis (Bio-Rad, Richmond, CA).

For the cell invasion assay, BD BioCoat™ Matrigel™ Invasion Chambers (BD Bioscience) were used according to the manufacturer’s protocol and as described previously.28 Briefly, the cells were incubated for 24 hr at 37°C and allowed to pass through the membrane. Afterward, the noninvading cells were removed from the upper surface of the membrane. The cells on the lower surface of the membrane were fixed with methanol and stained with hematoxylin and eosin, and the number of cells was counted. The chi-square test was performed to assess the statistical difference in the invasion rates, and statistical significance was accepted when $p < 0.05$.

**Results**

**Identification of genes amplified via DMs**

DMs represent the tumorigenesis manifestation of proto-oncogene amplification.22 To acquire the molecular characteristics of genes amplified in tumor cells, we performed an Affymetrix SNP Array 6.0 analyses to verify the amplification regions in human colorectal cancer NCI-H716 cells. Four amplified regions (>3-fold) were identified in NCI-H716 cells: 8q24.12 (121 034 440–121 537 936), 8q24.13 (121 999 452–122 552 404), 8q24.21 (125 541 866–128 978 180) and 10q26.13 (123 172 840–123 617 816) (Fig. 1a). There are 15 genes (DEPC6, COL14A1, MRPL13, NDUFB9, MTSS1, ZNF572, SQLE, KIAA0196, NSMCE2, TRIB1, FAM84B, POU5F1B, MYC, FGFR2 and ATE1) located in these four amplified regions (Fig. 1a). As overexpression of the genes is effective for their function in tumor cells, we performed quantitative reverse transcriptase-PCR (qRT-PCR) analysis to determine whether these genes were overexpressed when compared with normal colon tissue (Fig. 1b). The results showed that ten genes, NDUFB9, MTSS1, ZNF572, SOLE, KIAA0196, NSMCE2, TRIB1, FAM84B and MYC, located on 8q24.13 and 8q24.21 and FGFR2 located on 10q26.13 were at least 2-fold overexpressed in the cancer cells compared to the normal colon tissue (Fig. 1b). Subsequently, we performed quantitative PCR (qPCR) analysis to determine whether these genes were amplified in NCI-H716 cells. The results showed that all of the overexpressed genes, NDUFB9, MTSS1, ZNF572, SOLE, KIAA0196, NSMCE2, TRIB1, FAM84B, MYC and FGFR2, were amplified by at least 2-fold in the cancer cells when compared to the normal human peripheral blood DNA (Fig. 1c). Therefore, we found ten genes that are amplified and overexpressed in NCI-H716 cells.

Amplified genes might exist on DMs and/or at HSRs in cancer cells.29 To ascertain whether the amplified genes were located on DMs, fluorescence in situ hybridization (FISH) analysis was performed. Six BAC clones specifically covering the ten amplified genes (NDUFB9, MTSS1, ZNF572, SOLE, KIAA0196, NSMCE2, TRIB1, FAM84B, MYC and FGFR2) were amplified by at least 2-fold in the cancer cells compared to the normal colon tissue (Fig. 1b). Subsequently, we performed quantitative PCR (qPCR) analysis to determine whether these genes were amplified in NCI-H716 cells. The results showed that all of the overexpressed genes, NDUFB9, MTSS1, ZNF572, SOLE, KIAA0196, NSMCE2, TRIB1, FAM84B, MYC and FGFR2, were amplified by at least 2-fold in the cancer cells when compared to the normal human peripheral blood DNA (Fig. 1c). Therefore, we found ten genes that are amplified and overexpressed in NCI-H716 cells.

Amplified genes might exist on DMs and/or at HSRs in cancer cells.29 To ascertain whether the amplified genes were located on DMs, fluorescence in situ hybridization (FISH) analysis was performed. Six BAC clones specifically covering the ten amplified genes (NDUFB9, MTSS1, ZNF572, SOLE, KIAA0196, NSMCE2, TRIB1, FAM84B, MYC and FGFR2) were amplified by at least 2-fold in the cancer cells when compared to the normal human peripheral blood DNA (Fig. 1c). Therefore, we found ten genes that are amplified and overexpressed in NCI-H716 cells.

**Figure 3.** The amplification levels of the DM-carried genes are reduced in NCI-H716 shRNA cells. (a–g) The amplification levels of the DM-carried genes NDUFB9, MTSS1, NSMCE2, TRIB1, FAM84B, MYC and FGFR2 were examined in each shRNA NCI-H716 cell line and control cell line.
Carcinogenesis

MYC expression of shRNA cells (Supporting Information Figs. 2A–2G), and the FAM84B to the vector control cells (Figs. 2A–2F). We also confirmed this result in the SK-PN-DW knockdown cells (Supporting Information Fig. 1C). Furthermore, in the sh-FAM84B NCI-H716 cells, we found no DMs in 16.5% of the karyotypes, but we observed a large number of very small, sediment-like DMs in ~65.2% of the karyotypes (Fig. 2G). These results indicate that knockdown of the amplified genes induced genomic instability and abolished DMs formation in the tumor cells.

The production of DMs is abolished in DM-carried-gene knockdown cells, resulting in the reduced amplification of DM-carried genes

Amplified genes play critical roles in tumor cells. To further address the role of the amplified genes contained in the DMs of tumor cells, we selected gene-silencing siRNAs to target seven of the above DM-carried genes (Supporting Information Table 3); we also generated pSuper-short hairpin RNA (shRNA) expression vectors to knock down the expression of these genes. Immunoblotting and qRT-PCR analyses showed that the expression of NDUFB9, MTSS1, NSMCE2, TRIB1, FAM84B, MYC and FGFR2 decreased in stable NCI-H716 shRNA cells (Supporting Information Figs. 2A–2G), and the expression of MYC also decreased in stable SK-PN-DW shRNA cells (Supporting Information Fig. 1B).

We next examined whether knockdown of these amplified genes affected the production of DMs. We performed a DM counting assay on the karyotypes of each NCI-H716 shRNA cell. Interestingly, we found that the number of DMs was significantly decreased in the knockdown cells when compared to the vector control cells (Figs. 2A–2F). We also confirmed this result in the SK-PN-DW knockdown cells (Supporting Information Fig. 1C). Furthermore, in the sh-FAM84B NCI-H716 cells, we found no DMs in 16.5% of the karyotypes, but we observed a large number of very small, sediment-like DMs in ~65.2% of the karyotypes (Fig. 2G). These results suggest that along with the loss of DMs, the amplification levels of the DM-carried genes decreased; the exception to this might be a result of an adaptation of a particular gene under suppression conditions.

Table 1. Micronuclei counts from NCI-H716 knockdown cells

| NCI-H716 cells | No. of cells | No. of cells with MN | MN frequency (×10⁻²) | No. of MN+/MN | MN+/MN (%) | MN+ frequency (×10⁻²) | Fold change over control | No. of MN− | MN−/MN (%) | MN− frequency (×10⁻²) | Fold change over control |
|----------------|-------------|---------------------|---------------------|--------------|-----------|---------------------|------------------------|------------|------------|---------------------|------------------------|
| sh-control     | 135         | 9                   | 6.67                | 5            | 55.56     | 3.70                | 1.00                   | 4           | 44.44      | 2.96                | 1.00                   |
| sh-NDUFB9      | 291         | 65                  | 22.34               | 55           | 86.62     | 18.90               | 5.11                   | 10          | 15.38      | 3.44                | 1.16                   |
| sh-MTSS1       | 203         | 34                  | 16.75               | 26           | 76.47     | 12.81               | 3.46                   | 8           | 23.53      | 3.94                | 1.33                   |
| sh-control     | 228         | 20                  | 8.77                | 18           | 90.00     | 7.89                | 1.00                   | 2           | 10.00      | 0.88                | 1.00                   |
| sh-NSMCE2      | 256         | 56                  | 21.88               | 43           | 76.79     | 16.80               | 2.13                   | 13          | 23.21      | 5.08                | 1.77                   |
| sh-control     | 135         | 9                   | 6.67                | 5            | 55.56     | 3.70                | 1.00                   | 4           | 44.44      | 2.96                | 1.00                   |
| sh-TRIB1       | 273         | 27                  | 9.89                | 13           | 48.15     | 4.76                | 1.29                   | 14          | 51.85      | 5.13                | 1.73                   |
| sh-control     | 180         | 19                  | 10.56               | 11           | 57.89     | 6.11                | 1.00                   | 8           | 42.11      | 4.44                | 1.00                   |
| sh-FAM84B      | 107         | 11                  | 10.28               | 5            | 45.45     | 4.67                | 0.76                   | 6           | 54.55      | 5.61                | 1.26                   |
| sh-control     | 287         | 42                  | 14.63               | 37           | 88.10     | 12.89               | 1.00                   | 5           | 11.90      | 1.74                | 1.00                   |
| sh-MYC1        | 143         | 28                  | 19.58               | 23           | 82.14     | 16.08               | 1.25                   | 5           | 17.86      | 3.50                | 2.01                   |
| sh-control     | 370         | 11                  | 2.97                | 10           | 90.91     | 2.70                | 1.00                   | 1           | 9.09       | 0.27                | 1.00                   |
| sh-FGFR2       | 361         | 30                  | 8.31                | 20           | 66.67     | 5.54                | 2.05                   | 10          | 33.33      | 2.77                | 10.26                  |

MN+ indicates cells with BAC hybridization signals in the MN; MN− indicates cells without BAC hybridization signals in the MN.

were selected as FISH probes and hybridized to metaphase spreads of NCI-H716 cells. The results showed that these six BACs all hybridized to DMs in the NCI-H716 cells (Fig. 1d). This result suggests that DMs carry these amplified genes in NCI-H716 cells.

Similarly, we also examined the high amplification areas and the amplified genes in the DM-containing SK-PN-DW tumor cells using Affymetrix SNP Array 6.0 analysis and qPCR analysis (data not shown). We identified that MYC was also amplified via DMs in SK-PN-DW tumor cells (Supporting Information Fig. 1A).

MN carrying DMs fragments are induced following knocking down of DM-carried genes

Because the number of DMs and the amplification levels of DM-carried genes decreased, we examined the fate of these DMs prior to being lost from the cells. We performed FISH analysis to detect the amplification and location of DMs in the interphase of each knockdown cell line using Cy3- or green-labeled BAC clones containing the DM-carried genes. We found obvious induction of MN in the NCI-H716 shRNA cells. The MN could be divided into two FISH results: positive...
MN (MN+) stained with both DAPI and Cy3, and negative MN (MN−) stained with DAPI only (Supporting Information Fig. 3). We counted the cells that produced MN, and the results are summarized in Table 1. We found the number of stably knockdown cells carrying MN with and without BAC signals increased; moreover, the percentage of cells that had MN greatly increased (Table 1). We further confirmed this result in SK-PN-DW knockdown cells (Supporting Information Table 4). These results imply that DMs participating in MN+ are lost from cancer cells. The induction of MN+ is consistent with the above results concerning the decrease in the number of DMs and the amplification level of the carried genes. We speculate that the formation of MN+ may be associated with the loss of DMs.

Suppression of the DM-carried genes caused DNA damage in tumor cells
Low concentrations of HU have been found to cause DNA damage, detectable as γH2AX foci, in cells.12 We wanted to determine whether the suppression of the DM-carried genes could cause DNA damage in addition to the observed DM loss. We performed immunofluorescence analysis to detect the amount of γH2AX signals in three knockdown NCI-H716 cell lines. We grouped cells into four categories based on the amount of signals in each cell (Fig. 4a). The Mann–Whitney U-test was used to assess the significant differences in the γH2AX signals in the knockdown and control cells. A corrected p value less than 0.003 was considered significant. From the analysis, we found more cells with γH2AX foci in the NCI-H716 shRNA knockdown cells than the control cells. This was consistent with the immunoblot analysis of γH2AX expression (Fig. 4b). We further confirmed this result in SK-PN-DW knockdown cells, and using the Mann–Whitney U-test, a corrected p value less than 0.005 was considered statistically significant (Supporting Information Fig. 1D). The results indicate that suppression of the DM-carried genes is effective in inducing γH2AX foci formation in these cells. This suggests that the knocking down of the DM-carried genes can result in genomic instability, as well as DNA damage, and can lead to the loss of DMs from tumor cells.

Suppression of the DM-carried genes reduced malignant behavior
The amplification of DM-carried genes plays important roles in tumor cells; therefore, we evaluated the effect of the suppression of the DM-carried genes, as well as the loss of DMs, on the physiological functions of the cells. We examined the cell growth rate of three knockdown NCI-H716 cell lines. We found that cell proliferation was impaired in each cell line when compared to the control cell line (Fig. 5a). Knocking down the three amplified genes induced a notable increase in the percentage of cells in G1 phase (Fig. 5b). These results demonstrate that the expression of the DM-carried amplified genes is essential for the physiological function of tumor cells.

The ability of the cells to invade and migrate to the periphery of normal tissue is an important characteristic of tumor cells. To further examine the invasion of cells stably transfected with shRNA, we performed a basement membrane invasion assay after 24 hr of subculture. All three knockdown cell lines showed a significant decrease in cell invasion compared to the control cell line (Fig. 5c, Supporting Information Table 5). The results demonstrate that the DM-carried genes in tumor cells contribute to the cell’s invasive characteristics.

Discussion
DMs are cytogenetic hallmarks of extra-chromosome genomic amplification, and many DMs are found in the
malignant tumor cells.\textsuperscript{22} Our study focused on the function of DMs and gene amplification in malignant tumor cells. Using the Affymetrix SNP Array 6.0 analyses, we identified the regions of high amplification and the amplified genes located in these regions. We then tested the mRNA transcription and verified the DNA amplification of these genes. DMs are a major cytogenetic characteristic of malignant tumor cells; thus, we investigated the location of these amplified genes and identified the genes that were amplified via DMs.

To test the role of these DM-mediated amplified and overexpressed genes in malignant tumor cells, we used an

\begin{figure}
\centering
\includegraphics[width=\textwidth]{figure5}
\caption{Suppression of the DM-carried genes reduces cell proliferation, causes a G1 arrest and reduces cell invasion. (a) The growth of shRNA NCI-H716 cells decreased. The OD value of the cells was measured every day for 4–6 days and plotted. (b) The cell cycle distribution of sh-NMCE2, sh-MYC, sh-FGRF2 and sh-control NCI-H716 cells was determined using FACS analysis. (c) One representative trial of a cell invasion assay is shown for the shRNA NCI-H716 cells. [Color figure can be viewed in the online issue, which is available at wileyonlinelibrary.com.]
\end{figure}
RNAi system to knock down the expression of these genes. We generated sh-NDUFB9, sh-MTSS1, sh-NSMCE2, sh-TRIB1, sh-FAM84B, sh-MYC, and sh-FGFR2 stable knockdown NCI-H716 and SK-PN-DW cell lines using the pSuper-shRNA system. Amazingly, when the DM-carried genes were suppressed, the number of DMs declined in each knockdown cell line compared to the control cell line. In the sh-FAM84B knockdown cells, in particular, we did not detect DMs in 16.5% of the cells, but there were many very small DMs in 65.2% cells. These results indicate that the suppression of DM-carried genes led to genomic instability. Gene amplification is a significant event in these cell lines, so we investigated the amplification levels of the DM-carried genes in these knockdown cells. As the number of DMs decreased, the amplification levels of most DM-carried genes also decreased in these gene knockdown cells compared to the control cells.

As described previously, elimination of the amplified genes was accelerated by treating cells with a low dose of HU, and the elimination was accompanied by the specific inclusion of DMs into MN.12,30 The elimination of DMs into MN can also be induced by a broad range of DNA replication inhibitors used at low doses, as well as low-dose radiation therapy.15,30 We were very interested in whether DMs would gather into MN when the expression of the DM-carried genes was suppressed. To trace the DMs and the DM-carried genes in the knockdown cells, we performed FISH analysis using BAC clones containing the DM-carried genes as probes to detect MN formation. We designated the positive signals as MN+ (DM-type MN), which may mediate the elimination of the DMs. We designated the negative signals as MN− (chromosome-type MN); this type arises from a centric whole chromosome that was bound by microtubules from both spindle poles. This type of MN has no DMs and thus would have no signal due to the lack of hybridization of the DM-specific probes.

DMs incorporate into MN, which leads to the elimination of the DMs from the cell through extrusion. Both MN with or without signals were increased in the shRNA stably transfected cells compared to the control cells. The percentage of MN+ increased in the shRNA cells, which suggests that the DMs are in the MN expelled from the cells. We observed the aggregation of DM-carried genes in interphase, illustrating the subsequent extrusion from the nucleus and the formation of MN that will be expelled from the cell. As previously reported, a plasmid was first multimerized to form a large circular molecule that resembles a DM and was then integrated into the chromosome, forming HSR.31,32 However, in our study, we did not detect HSR in the metaphase nucleus. These results indicate that knocking down the DM-carried genes leads to the incorporation of DMs into MN, resulting in DM elimination from the cells and reduced amplification of the DM-carried genes. In addition, reducing the amplification of the DM-carried genes consequently causes a decline in DM formation.

A previous study showed that low-dose HU could induce γH2AX foci throughout the nucleus during S-phase.12 It is reasonable to assume that HU induced γH2AX foci not only on chromosome arms but also in DMs.12 Unexpectedly, DNA damage in DMs and in chromosomes has different consequences. The cell cycle will be arrested to restore damaged DNA in chromosomes, but DMs heavily stained with γH2AX signals always aggregated at metaphase, and they remained behind when the chromatids separated during anaphase, thus generating MN. We have performed immunofluorescence to determine the amount of γH2AX foci in the knockdown cells. We grouped cells into four categories based on the amount of γH2AX foci present in the knockdown cells using immunofluorescence, and we found that knockdown cells showed an increased amount of γH2AX foci compared to control, which is consistent with the immunoblot results.

We speculated that suppression of the DM-carried genes is effective at inducing γH2AX foci formation, which is a sensitive DNA damage marker. The underlying cause might be that deficiency of the genes that are implicated in tumorigenesis would lead to genomic instability and DNA recombination.33 DNA damage is highly cytotoxic and is associated with genomic instability. These results indicate that γH2AX foci increased in the gene knockdown cells, which provides a strong link between DNA damage and the loss of DM. Knocking down DM-carried genes can cause DNA damage and can lead to DM loss from tumor cells through the extrusion of MN.

Elimination of DM-amplified genes from tumor cells via MN leads to a reversion in tumor phenotype and cellular differentiation.20,21 We examined the physiological functions of the shRNA cells. We found that knocking down all the DM-carried genes led to a marked decrease in cell proliferation ability and cell invasion ability. The decrease in the number of DMs and in the amplification levels of the DM-carried genes in malignant tumor cells might result in cell cycle arrest and reduction of the cell invasion ability. Using the DM-containing human malignant tumor cell lines as models, we conclude that the formation of DMs is associated with the amplification and expression of the DM-carried genes.

Acknowledgements
This work was supported by the International Science & Technology Cooperation Program of China (2013DFA31610 to S.F.), the Program for Changjiang Scholars and Innovative Research Team in University (IRT1223 to Y.Y.), the National Natural Science Foundation of China (31000626 and 31271347 to W.S.), and the New Century Support Program for the Excellent Scholar, Ministry of Education of China (NCET-10-0149 to W.S., NCET-11-0954 to Y.Y.).

Conflict of interest
The authors declare no conflict of interest.
References

1. Albertson DG, Collis C, McCormick F, et al. Chromosome aberrations in solid tumors. Nat Genet 2003;34:369–76.

2. Fletcher JA. Cytogenetics of solid tumors. In: Gershn SL, Keagle MB, eds. The principles of clinical cytogenetics, 2nd edn. Totowa, NJ: Humana Press, 2005. Section IV, 421–51.

3. Myllykangas S, Knuutila S. Manifestation, mechanisms and mysteries of gene amplifications. Cancer Lett 2006;232:79–89.

4. Schwab M. Amplification of oncogenes in human cancer cells. Biosci Rep 1998;20:473–9.

5. Schimke RT. Gene amplification and methotrexate resistance in cultured animal cells. Harvey Lect 1980;76:1–25.

6. Stark GR, Wahl GM. Gene amplification. Annu Rev Biochem 1984;53:447–91.

7. Windle B, Draper BW, Yin YX, et al. A central role for chromosome breakage in gene amplification, deletion formation, and ampiclon integration. Genes Dev 1991;5:160–74.

8. Masuda A, Takahashi T. Chromosome instability in human lung cancers: possible underlying mechanisms and potential consequences in the pathogenesis. Oncogene 2002;21:6884–97.

9. Kuttler F, Mai S. Formation of non-random extrachromosomal elements during development, differentiation and oncogenesis. Semin Cancer Biol 2007;17:56–64.

10. Deng X, Zhang L, Zhang Y, et al. Double minute chromosomes in mouse methotrexate-resistant cells studied by atomic force microscopy. Biochem Biophys Res Commun 2006;346:1228–33.

11. Benzer SE, Wahl GM, Von Hoff DD. Double minute chromosomes and homogeneously staining regions in tumors taken directly from patients versus in human tumor cell lines. Anticancer Drugs 1991;2:11–25.

12. Shimizu N, Misaka N, Utani K. Nonselective DNA damage induced by a replication inhibitor results in the selective elimination of extrachromosomal double minutes from human cancer cells. Genes Chromosomes Cancer 2007;46:865–74.

13. Eckhardt SG, Dai A, Davidson KK, et al. Induction of differentiation in HL60 cells by the reduction of extrachromosomally amplified c-myc. Proc Natl Acad Sci USA 1994;91:6674–8.

14. Von Hoff DD, McGill JR, Forseth BJ, et al. Elimination of extrachromosomally amplified MCF genes from human tumor cells reduces their tumorigenicity. Proc Natl Acad Sci USA 1992;89:8165–9.

15. Schoenlein PV, Barrett JT, Kulharya A, et al. Radiation therapy depletes extrachromosomally amplified drug resistance genes and oncogenes from tumor cells via micronuclear capture of episomes and double minute chromosomes. Int J Radiat Oncol Biol Phys 2003;55:1051–65.

16. Sanchez AM, Barrett JT, Schoenlein PV. Fractionated ionizing radiation accelerates loss of amplified MDR1 genes harbored by extrachromosomal DNA in tumor cells. Cancer Res 1998;58:3485–54.

17. Norppa H, Falck GC. What do human micronuclei contain? Mutagenesis 2003;18:221–33.

18. Shimizu N, Itoh N, Utiyama H, et al. Selective entrapment of extrachromosomally amplified DNA by nuclear budding and micronucleation during S phase. J Cell Biol 1998;140:1307–20.

19. Heddle JA, Cimino MC, Hayashi M, et al. Micronuclei as an index of cytogenetic damage: past, present, and future. Environ Mol Mutagen 1991;18:277–91.

20. Utani K, Kawanoto JK, Shimizu N. Micronuclei bearing acentric extrachromosomal chromatin are transcriptionally competent and may perturb the cancer cell phenotype. Mol Cancer Res 2007;5:695–704.

21. Shimizu N, Nakamura H, Kadota T, et al. Loss of amplified c-myc genes in the spontaneously differentiated HL-60 cells. Cancer Res 1994;54:3561–7.

22. Camps J, Nguyen QT, Padilla-Nash HM, et al. Integrative genomics reveals mechanisms of copy number alterations responsible for transcriptional deregulation in colorectal cancer. Genes Chromosomes Cancer 2009;48:1002–17.

23. Sun W, Li H, Yu Y, et al. MEKK3 is required for lysophosphatidic acid-induced NF-kappaB activation. Cell Signal 2009;21:1488–94.

24. Kanda T, Kamiya M, Maruo S, et al. Symmetrical localization of extrachromosomally replicating viral genomes on sister chromatids. J Cell Sci 2007;120:1529–39.

25. Yihui F, Xiaohong Z, Jing B, et al. Ultrastructural organization of premature condensed chromosomes at S-phase as observed by atomic force microscopy. Appl Surf Sci 2007;253:6.

26. Guan XY, Trent JM, Meltzer PS. Generation of band-specific painting probes from a single microdissected chromosome. Hum Mol Genet 1993;2:1117–21.

27. Zhang W, Zhu J, Bai J, et al. Comparison of the inhibitory effects of three transcriptional variants of CDKN2A in human lung cancer cell line A549. J Exp Clin Cancer Res 2010;29:74.

28. Meng XN, Jin Y, Yu Y, et al. Characterisation of fibronectin-mediated FAK signalling pathways in lung cancer cell migration and invasion. Br J Cancer 2009;101:327–34.

29. Albertson DG. Gene amplification in cancer. Trends Genet 2006;22:447–55.

30. Shimizu N. Molecular mechanisms of the origin of micronuclei from extrachromosomal elements. Mutagenesis 2011;26:119–23.

31. Shimizu N, Hashizume T, Shingaki K, et al. Amplification of plasmids containing a mammalian replication initiation region is mediated by controllable conflict between replication and transcription. Cancer Res 2003;63:5281–90.

32. Wahl GM. The importance of circular DNA in mammalian gene amplification. Cancer Res 1989;49:1333–40.

33. Oh DH, Rigan D, Cho A, et al. Deficiency in the nuclear-related factor erythroid 2 transcription factor (Nrf1) leads to genetic instability. FEBS J 2012;279:4121–30.